A discussion of micrornas in cancers

Current Bioinformatics

Volumn 9, Issue 5, 2014, Pages 453-462

  Hua, Shi ^a,b   Yun, W ^b   Zhiqiang, Zeng ^b   Zou, Quan ^a  

^a XIAMEN UNIVERSITY   (China)

^b XIAMEN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; DISEASES;

BIOLOGICAL PROCESS; CANCER CELLS; CANCER DEVELOPMENT; CANCER PATHOGENESIS; CELL APOPTOSIS; CELL DEVELOPMENT; CELL DIFFERENTIATION; CELL PROCESS; MOLECULAR LEVELS; REGULATORY FUNCTIONS;

RNA;

MICRORNA; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BIOGENESIS; BREAST CANCER; CANCER CELL; CANCER THERAPY; COLORECTAL CANCER; HUMAN; LEUKEMIA; LUNG CANCER; NEOPLASM; NONHUMAN; ONCOGENE; PROSTATE CANCER;

EID: 84911361683     PISSN: 15748936     EISSN: 2212392X     Source Type: Journal    
DOI: 10.2174/1574893609666140804221135     Document Type: Article

References (87)

1. Ambros V, The functions of animal microRNAs. Nature 2004; 431: 350-5.
2. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115:787-798.
3. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol. 2005; 3:e85.
4. Garzon R, Guido M, Carlo MC. Targeting microRNAs in cancer: rationale, strategies and challenges. Nature reviews Drug discovery. 2010; 9: 775-789.
5. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-54.
6. Griffiths JS. The microRNA Registry. Nucleic Acids Res 2004; 32: D109-11.
7. Zou Q, Mao Y, Hu LL, Wu YF, Ji ZL. miRClassify: An advanced web server for miRNA family classification and annotation. Computers in Biology and Medicine. 2014; 45:157-160
8. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
9. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-7.
10. Lowery AJ, Miller N, Devaney A, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Research 2009; 11: R27
11. Wang QC, Wei LY, Guan XJ, et al. Briefing in Family Characteristics of MicroRNAs And Their Applications in Cancer Research. BBA-Proteins and Proteomics. 2014; 1844:191-197
12. Lu J, Getz G., Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
13. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415-9.
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
15. McDaneld TG.. MicroRNA: mechanism of gene regulation and application to livestock. J Anim Sci 2009; 87: E21-8.
16. Behm AI, Rehwinkel J, Doerks T, Stark A, Bork P, Izaurralde E. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev. 2006; 20:1885-1898
17. Wei LY, Huang Y, Qu YY, Jiang Y, Zou Q. Computational analysis of miRNA target identification. Current Bioinformatics. 2012; 7:512-525
18. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
19. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-6.
20. Sun Y, Fang R, Li C, et al. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun 2010; 396: 501-7.
21. Incoronato M, Garofalo M, Urso L, et al. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in nonsmall cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 2010; 70: 3638-46.
22. Roybal JD, Zang Y, Ahn YH, et al. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res 2010; 9: 25-35.
23. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010; 120: 1298-309.
24. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628-32.
25. Jiang L, Huang Q, Zhang S, et al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 2010; 10: 318.
26. Iorio MV, Ferracin M, Liu CG., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
27. Wang CY, Wei LY, Guo MZ, Zou Q. Computational Approaches on Detecting non-coding RNA. Current Genomics. 2013; 14: 371-377
28. Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-52.
29. Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 2006; 26: 8191-201.
30. Yu Z, Wang C, Wang M, et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 2008; 182: 509-17.
31. Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137: 1032-46.
32. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-803.
33. Jiang S, Zhang HW, Lu MH, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010; 70: 3119-27.
34. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859-64.
35. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-5.
36. Diana F, Di BJ, Sgarra R, et al. Differential HMGA expression and post-translational modifications in prostatic tumor cells. Int J Oncol 2005; 26: 515-20.
37. Takaha N. Hawkins AL, Griffin CA, Isaacs WB, Coffey DS. High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res 2002; 62: 647-51.
38. Wei JJ, Wu X, Peng Y, et al, Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res 2010; 17: 1297-305.
39. Hudson RS, Yi M, Esposito D, et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 2011; 40: 3689-703.
40. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-5.
41. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
42. Leite KR, Sousa-Canavez JM, Reis ST, et al. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol 2011; 29: 265-9.
43. Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009; 383: 280-5.
44. Shi XB, Xue L, Ma AH, et al. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011; 71: 538-549.
45. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
46. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006; 29: 903-6.
47. Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28: 1385-92.
48. Schimanski CC, Frerichs K, Rahman F. et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 2009; 15: 2089-96.
49. Tang JT, Wang JL, Du W, et al. MicroRNA 345, a methylationsensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer. Carcinogenesis 2011; 32: 1207-15.
50. Nie J, Liu L, Zheng W, et al. microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis 2011; 33: 220-5.
51. Cmarik JL, Min H, Hegamyer G, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA 1999; 96: 14037-42.
52. Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-36.
53. Huang Z, Huang S, Wang Q, et al. MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res 2011; 71: 2582-9.
54. Zhu L, Chen H, Zhou D, et al. MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med Oncol 2011; 29: 1037-43.
55. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007; 139: 809-19.
56. Santanam U, Zanesi N, Efanov A, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci USA 2010; 107: 12210-5.
57. Mraz M, Dolezalova D, Plevova K, et al. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood 2011; 119: 2110-3.
58. Rossi S, Shimizu M, Barbarotto E, et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010; 116: 945-52
59. Roman GJ, Agirre X, Jimenez VA, et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 2009; 27: 1316-22.
60. Li X, Liu J, Zhou R, et al. Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation. Br J Haematol 2009; 148: 69-79.
61. Rodriguez OP, Roman GJ, Vilas ZA, et al. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family. Br J Haematol 2011; 155: 73-83.
62. Mavrakis KJ, Van Der Meulen J, Wolfe AL, et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet 2011; 43: 673-8.
63. Fei J, Li Y, Zhu X, Luo X. miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML). PLoS One 2012; 7: e32834.
64. Rokah OH, Granot G, Ovcharenko A, et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One 2012; 7: e35501.
65. Pulikkan JA, Dengler V, Peramangalam PS, et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 2010; 115: 1768-78.
66. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105: 15535-40.
67. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-14.
68. Zou Q, Li JJ, Wang CY, Zeng XX. Approaches for recognizing disease genes based on network. BioMed Research International. 2014; 2014: 416232
69. Xu YG, Guo MZ, Liu XY, Wang CY, Liu Y. SoyFN: a knowledge database of soybean functional networks. Database. 2014; 2014: bau019.
70. Teng ZX, Guo MZ, Liu XY, et al. Measuring gene functional similarity based on group-wise comparison of GO terms. Bioinformatics. 2013; 29: 1424-32.
71. Wang D, Wang J, Lu M, et al. Inferring the human microRNA functional similarity and functional network based on microRNAassociated diseases, Bioinformatics. 2010; 26: 1644-50
72. Li Y, Qiu C, Tu J, et al. HMDD v2. 0: a database for experimentally supported human microRNA and disease associations. Nucleic acids research. 2014; 42: D1070-4.
73. Jiang QH, Wang YD, Hao YY, et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic acids research. 2009; 37: D98-104.
74. Yang Z, Ren F, Liu C, et al. dbDEMC: a database of differentially expressed miRNAs in human cancers. BMC genomics. 2010; 11: S5.
75. Xie B, Ding Q, Han H, et al. miRCancer: a microRNA-cancer association database constructed by text mining on literature. Bioinformatics 2013; 29:638-44.
76. Jiang Q, Hao YY, Wang GH, et al. Prioritization of disease microRNAs through a human phenome-microRNAome network. BMC Systems Biology 2010; 4: S2
77. Kertesz M, Iovino N, Unnerstall U, et al. The role of site accessibility in microRNA target recognition. Nature Genetics 2007; 39: 1278-84.
78. Lewis BP, Shih I, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-98.
79. Zou Q, Li XB, Jiang Y, Zhao YM, Wang GH. BinMemPredict: a Web server and software for predicting membrane protein types. Current Proteomics 2013; 10: 2-9.
80. Goh KI, Cusick ME, Valle D, et al. The human disease network. Proceedings of the National Academy of Sciences 2007; 104: 8685-90.
81. Chen X, Liu MX, Yan GY. RWRMDA: predicting novel human microRNA-disease associations. Molecular BioSystems 2012; 8: 2792-98
82. Trang P, Medina PP, Wiggins JF, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2009; 29: 1580-7
83. Furuta M, Kozaki KI, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31: 766-76.
84. Garzon R, Heaphy CE, Havelange V, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114: 5331-41.
85. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721-6.
86. Bhattacharya A, Jesse DZ, and Yan C. Somami R: a database for somatic mutations impacting microRNA function in cancer. Nucleic acids research 2014; 41: D977-82
87. Baer C, Rainer C, and Christoph P. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer research 2013; 73: 473-477.